Venture financing in the segment of pharmaceutical biotechnology in the Russian Federation

Abstract

One of the main directions of the pharmaceutical industry is the transition to the stage of commercialization of the results of intellectual activity and to the large-scale creation of global markets for new products and services. In recent years, the number of research conducted in the pharmaceutical industry has increased, and the most acute question is the active introduction of research results into mass production. The article provides an overview of the current state of venture financing in the biotechnology industry of the Russian Federation, as the most effective mechanism for financing promising applied research and, in particular, in the pharmaceutical biotechnology segment. The authors reviewed the main program documents affecting the development of biotechnology in Russia. The main venture funds that invest in pharmaceutical biotech companies are identified. The assortment portfolio of invested companies developed for the treatment of certain diseases was considered, and the main direction for the study was determined. The analysis of the funds that carry out the grant support of applied biotechnological research has been carried out. It allows to overcome the «sowing» stage of development of an innovative company and get initial research results. The main reasons for the slow development of venture capital investments in the biotech industry are identified and ways to overcome them are proposed.